Pfizer
Q2 2022 Earnings Call
Jul 28, 2022, 10:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good day, everyone, and welcome to Pfizer's second quarter 2022 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over to Mr. Chris Stevo, senior vice president and chief investor relations officer.
Please go ahead, sir.
Chris Stevo -- Senior Vice President and Chief Investor Relations Officer
Thank you, Chelsea. Good morning, everyone. Welcome to Pfizer's second quarter earnings call. We anticipate that this call will last 90 minutes.
I'm joined today by Dr. Albert Bourla, our chairman and CEO; Dave Denton, our CFO; and Mikael Dolsten, president of worldwide research and development and medical. Joining for the Q&A session, we will also have Angela Hwang, group president, Pfizer Biopharmaceuticals Group; Aamir Malik, our chief business innovation officer; William Pao, our chief development officer; and Doug Lankler, our general counsel. The materials of this call and other earnings-related materials are on the Investor Relations section of pfizer.com.
Please see our forward-looking statements disclaimer on Slide 3. And additional information regarding these statements and our non-GAAP financial measures is available in our earnings release and in our SEC Forms 10-K and 10-Q under Risk Factors and Forward-Looking Statements. Forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements. With that, I will turn the call over to Albert.
Albert Bourla -- Chairman and Chief Executive Officer
Thank you, Chris. Hello, everyone. I'm proud to say that Pfizer continued to deliver strong operational performance in the second quarter and has increased its full year 2022 operational financial forecast for revenue and adjusted diluted earning per shares, all while operating in a challenging foreign exchange environment. Compared with the second quarter of 2021, global revenues were up 53% operationally to $27.7 billion, and adjusted diluted EPS increased 100% operationally to $2.04.
Both results exceeded consensus analyst expectations, and the quarterly revenue figure represented the largest in Pfizer's history. Key growth drivers for the quarter include Paxlovid, Comirnaty, Eliquis, and Vyndaqel/Vyndamax globally and our Prevnar family of products in the U.S. Year to date, we have reached an estimated 845 million patients around the world with our innovative medicines and vaccines, which represents a 77% increase from the prior-year period. And we did all of this while also taking steps to help address broader issues impacting global health, including climate change, equitable access, and the war in Ukraine.